Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Advanced Solid Tumors × adavosertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Uterine Cervical Neoplasms 2 Advanced Solid Tumours 2 Vaginal Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Neoplasms 1 Myelodysplastic Syndromes 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Carcinoma, Endometrioid 1 Blast Crisis 1 Advanced Solid Tumors 1

Interventions

Carboplatin 3 Docetaxel 2 Cisplatin 2 BMS-753493 2 zimberelimab 1 tislelizumab 1 spartalizumab 1 pembrolizumab 1 olaparib 1 liposomal doxorubicin 1 linifanib 1 lenvatinib 1 ixabepilone 1 durvalumab 1 avelumab 1 avdoralimab 1 adavosertib 1 Nivolumab 1 N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 1 Maximum Tolerated Dose 1 Linoleic Acids, Conjugated 1 Lapatinib 1 Irinotecan 1 Ipilimumab 1 Injections 1 Ifosfamide 1 Gemcitabine 1 Fluorouracil 1 Doxorubicin 1 Dosage Forms 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05008913 2022-09-06

ADME

AstraZeneca

Phase 1 Terminated

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡